A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
A novel radiotracer has been identified that can detect nearly 30 types of cancer using positron emission tomography/computed tomography (PET/CT). This technology shows promise for new applications in noninvasive diagnosis, staging and treatment.
The Society of Nuclear Medicine and Molecular Imaging announced 13 new SNMMI Fellows, recognizing their outstanding contributions to the field. The recipients include past SNMMI presidents and experts in various areas of nuclear medicine and molecular imaging.
Researchers used PET/CT to evaluate coronary microvascular function in OSA patients and found a link between severe sleep apnea and impaired coronary flow reserve. The study suggests that patients with severe OSA should receive PET myocardial perfusion imaging to exclude coronary microcirculatory dysfunction.
Researchers developed a wearable vest to collect data for personalized therapy in patients with metastatic NETs. The device provides organ-specific measurement recordings within the patient's comfort, allowing for more effective treatment and improved progression-free survival.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A study found that PET/CT imaging can identify diseased areas in patients with extra-pulmonary tuberculosis, guiding personalized therapy. The test provides a whole-body survey, helping to estimate disease extent and predict treatment response.
Di Carli is recognized as an outstanding clinician-scientist, teacher, and mentor, known for pioneering work in cardiovascular radionuclide imaging and services. His research has contributed to understanding ischemic cardiac dysfunction and using positron emission tomography (PET) for guiding management of patients with end-stage heart...
A first-in-human Phase 1/Phase II study demonstrates the safety and efficacy of intravenous administration of technetium-99m tilmanocept for monitoring rheumatoid arthritis disease activity. The imaging agent binds to activated macrophages, providing joint-specific information on RA disease involvement.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
Researchers developed a new type of nuclear medicine scan that quickly and precisely diagnoses inflammation in IBD using monoclonal antibodies directed against specific innate immune cell markers. The immuno-PET scan has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases.
A novel radiopharmaceutical has proven effective in identifying nearly 30 types of malignant tumors with high uptake and image contrast. The tracer targets cancer-associated fibroblasts, which can contribute up to 90% of a tumor's mass.
A multicenter study found that deep learning analysis of single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) improved the diagnosis of obstructive coronary artery disease. The new method showed increased sensitivity and accuracy compared to traditional methods, leading to better patient outcomes.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
Researchers have discovered a new PET imaging biomarker that can better predict the progression of Alzheimer's disease. Microglial activation levels, as measured by TSPO-PET imaging, showed a significant correlation with cognitive outcomes in an amyloid mouse model.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.
Researchers have found that a new PET imaging agent, 18F-FFNP, can measure changes in progesterone receptor levels resulting from hormone therapy for breast cancer patients. This could provide an earlier indicator of therapy effectiveness and inform individualized treatment decisions.
Researchers found that combining iodine-123 metaiodobenzylguanidine (123I-MIBG) SPECT imaging with cardiac magnetic resonance imaging (MRI) helps identify specific subsets of heart tissue more prone to arrhythmias. This approach enables physicians to achieve improved VT suppression and shorter procedure times.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
Researchers developed a novel SPECT tracer to image c-Met expression in NSCLC, producing clearer images in less time and reducing radiation exposure. The tracer showed high specificity and rapid clearance from the body, making it potentially suitable for clinical use.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
A new imaging method targets cancer-associated fibroblasts to diagnose widespread tumors like breast, colon, and pancreas cancer with better accuracy and less inconvenience. The tracer shows high tumor uptake and image contrast, making it a promising strategy for detection and treatment of malignant tumors.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized contributions from April Mann, Cybil Nielsen, Cheryl Rickley, and Lynne Roy for their dedication to advancing nuclear medicine technology. The awards highlight the impact of these individuals on education, advocacy, and service in the field.
The Journal of Nuclear Medicine's impact factor increased by 12% in 2017, ranking fifth among medical imaging journals. Citations to the journal rose from 24,977 to 27,101.
A new PET imaging method evaluates the extent of rheumatoid arthritis inflammation by targeting translocator protein (TSPO) expression in joint lining tissue. The study demonstrates that TSPO PET can image not only synovial macrophages but also activated synovial fibroblasts, a critical process in RA pathogenesis.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the selection of 14 new Fellows, recognizing their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
Researchers have developed a novel approach to pretargeted radioimmunotherapy, which has shown complete responses in several solid tumor types using the beta-emitting lutetium-177 and alpha-emitting actinium-225. The new approach offers greater versatility of treatment for various solid tumors and clinical situations.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Richard L. Wahl, MD, has been recognized for his pioneering work in radioimmunotherapy, PET scans, and fusion imaging. His research has significantly contributed to understanding cancer prognosis, treatment response, and the importance of metabolic activity.